A new antibody cocktail prevents COVID-19 in the chronically ill
Key Highlights: A novel monoclonal antibody treatment protects chronically ill adults from COVID-19. Provent is not the first clinical trial to examine AZD7442 but it is the first to produce encouraging results. The Provent trial’s preliminary data analysis comprises six months of follow-up, with another nine months of observation to come. Protecting Susceptible patients A […]
A new antibody cocktail prevents COVID-19 in the chronically ill Read More »